Breaking News

These “Breaking news” sessions feature presentations on recent clinical trials, new developments in experimental science, and updates on other hot topics.

Sunday 06 May 15:45
LATE BREAKING INSIGHT INTO LIPOPROTEIN FUNCTION

Chair:
  • Erik S. Stroes, The Netherlands
  • Philippe Moulin, France

EICOSAPENTAENOIC ACID INHIBITED OXIDIZED HDL-INDUCED LOSS OF ENDOTHELIAL NITRIC OXIDE RELEASE AS COMPARED TO FENOFIBRATE OR NIACIN IN VITRO

R. Preston Mason, Beverly, MA, USA

DIFFERERENTIAL AND ANTAGONISTIC REGULATION OF TRANSENDOTHELIAL TRANSPORT OF HDL AND LDL BY SPHINGOSINE-1-PHOSPHATE RECEPTORS 1 AND 3

Arnold von Eckardstein, Basel, Switzerland

THE APOLIPOPROTEIN M/S1P AXIS CONTROLS TRIGLYCERIDE METABOLISM AND BROWN FAT ACTIVITY

Christina Christoffersen, Copenhagen, Denmark

A DEEP INTRONIC VARIANT IN LDLR CAUSING FAMILIAL HYPERCHOLESTEROLEMIA: TIME TO WIDEN THE SCOPE?

Rens Reeskamp, Amsterdam, The Netherlands

LPA VARIANTS, RISK OF CORONARY DISEASE, AND ESTIMATED CLINICAL BENEFIT OF LIPOPROTEIN(A) LOWERING THERAPIES: A MENDELIAN RANDOMIZATION ANALYSIS

Brian A. Ference, Cambridge, United Kingdom

Monday 07 May 15:45
LATE BREAKING – CLINICAL STUDIES

Chair:
  • Francois Mach, Switzerland
  • Eran Leitersdorf, Israel

LIPID MANAGEMENT OF PATIENTS WITH CORONARY HEART DISEASE IN 27 COUNTRIES IN EUROPE: RESULTS OF EUROASPIRE V SURVEY OF THE EUROPEAN SOCIETY OF CARDIOLOGY

Kornelia Kotseva, London, United Kingdom

NEW DATA ON THE CANTOS TRIAL

Peter Libby, Boston/Paris, USA/France

EFFECT OF AN RNAI THERAPEUTIC TARGETING PCSK9 ON ATHEROGENIC LIPOPROTEINS: PRE-SPECIFIED SECONDARY ENDPOINTS IN ORION 1

Kausik Ray, London, United Kingdom

LIPOPROTEIN(A), PCSK9 INHIBITION AND CARDIOVASCULAR RISK: INSIGHTS FROM THE FOURIER TRIAL

Michelle O'Donoghu, Boston, USA